Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
What is your preferred intervention for diffuse severe ISR involving two layers of stent?
Answer from: at Community Practice
Drug coated balloons
Sign In
or
Register
to read more
Answer from: at Community Practice
LASER atherectomy, high pressure PTCA to ensure stents are fully expanded preferably ICUS confirmed, followed by Brachytherapy.
Sign In
or
Register
to read more
Answer from: at Academic Institution
Atherotomy (SCOREFLEX, angiosculpt, or cutting balloon) plus DEB.
Sign In
or
Register
to read more
Answer from: at Academic Institution
I agree with drug-coated balloon.
Sign In
or
Register
to read more
30238
30269
30264
30686
Related Questions
How do the results of CREST-2 influence your recommendations on screening for asymptomatic carotid stenosis?
What advice would you give to patients with refractory nausea and vomiting at home who are unable to take oral medications but have recently had a PCI and stent placement requiring uninterrupted DAPT?
When is a reasonable amount of time for patients to be on 90 mg BID of ticagrelor before transitioning to 60 mg BID following PCI?
Do you always give 325mg aspirin if not already loaded with antiplatelets prior to the start of every LHC, even just for diagnostics in the absence of ACS?
What are your preferred femoral vascular closure devices for severely calcified femoral artery vessels following PCI, especially with higher sticks, and why?
Do you recommend stepwise de-escalation of dual antiplatelet therapy for patients at high risk of bleeding who have undergone drug-coated balloon angioplasty?
Do you prefer the routine use of bivalirudin over UFH during PCI cases in patients presenting with ACS?
Do you prefer using echocardiographic guided or SmartAssist guided help for Impella repositioning, and why?
What are your key takeaways regarding the difference in findings for BETA-MI DANBLOCK and REBOOT in patients post-MI with LVEF >40%?
During a coronary intervention, if the activated clotting time (ACT) is not within the therapeutic range despite administering weight-based unfractionated heparin, what alternative options do you consider?